Abstract
The development of multiple successful vaccines against SARS-CoV-2 provided much-needed good news at the end of 2020. The first vaccines approved in the UK were the Pfizer–BioNTech BNT162b2 mRNA-based vaccine and the Oxford–AstraZeneca non-replicating adenoviral-vectored vaccine ChAdOx1 nCoV-19.1,2 Responses to single-dose vaccine were not reported in published clinical trials; however, in December, 2020, the UK Joint Committee on Vaccination and Immunisation adopted the strategy of delaying second vaccination to 12 weeks to maximise the public health impact of first-dose vaccination.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
